The recent status of multidrug- and extensively drug-resistant tuberculosis in Korea

Tuberculosis and Respiratory Diseases

Volumn 68, Issue 3, 2010, Pages 146-154

  Kim, Sun Young ^a   Kim, Hee Jin ^b   Kim, Chang Ki ^b   Yoon, Hye Ryung ^c   Bae, Hye Gyung ^d   Lee, Sun Hwa ^e   Sung, Nackmoon ^f   Kim, Dae Yeon ^g   Lee, Gang Young ^h   Cho, Young Soo ^h   Lee, Sang Do ^a   Kim, Woo Sung ^a   Kim, Dong Soon ^a   Shim, Tae Sun ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Korean Institute of Tuberculosis   (South Korea)

^c Seoul Medical Science Institute   (South Korea)

^d Green Cross Company   (South Korea)

^e NeoDin Medical Institute   (South Korea)

^f National Masan Hospital   (South Korea)

^g National Mokpo Tuberculosis Hospital   (South Korea)

^h Seobuk Hospital   (South Korea)

Author keywords

Extensively drug resistant tuberculosis; Korea; Microbial sensitivity tests; Multidrug resistant; Tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; ENVIOMYCIN; ISONIAZID; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ARTICLE; DRUG SENSITIVITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH STATUS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; SOUTH KOREA;

EID: 77951283942     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2010.68.3.146     Document Type: Article

References (12)

1. Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997: World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998;338:1641-1649
2. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-1580 (Pubitemid 44780738)
3. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009;136:420-425
4. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 2007;11:571-576
5. Bae GH. National tuberculosis control program in Korea: actions for TB elimination. Commun Dis Mon Rep 2006;17:1-10.
6. Jeon D, Shin D, Kang H, Sung N, Kweon K, Shin E, et al. Trend of multidrug and extensively drug resistant tuberculosis in a tuberculosis referral hospital, 2001-2005. Tuberc Respir Dis 2008;64:187-193
7. Kim BJ, Lee IH, Lee DH, Bai GH, Kong SJ, Lee SH, et al. The current status of multidrug-resistant tuberculosis in Korea. Tuberc Respir Dis 2006;60:404-411 (Pubitemid 44125105)
8. Case definition for extensively drug-resistant tuberculosis. Wkly Epidemiol Rec 2006;81:408.
9. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002-2007: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009;373:1861-1873
10. World Health Organization. Global map and information on XDR-TB: countries that had reported at least one XDR-TB case by September 2009 [internet]. Geneva: World Health Organization; 2009 [cited 2009 Dec 20]. Available from: http://www.who.int/tb/challenges/xdr/xdr-map-sep09.pdf.
11. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs: worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006;55:301-305
12. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008;178:1075-1082